Exploring how extra DNA fragments affect cancer and stress responses
Understanding Epigenetic Regulation of Copy Number Heterogeneity
['FUNDING_OTHER'] · UNIVERSITY OF COLORADO DENVER · NIH-10842722
This study is looking at special pieces of DNA that can affect how our bodies develop and how diseases like cancer grow, with the hope that understanding them better will help create new treatments for patients.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF COLORADO DENVER (nih funded) |
| Locations | 1 site (Aurora, UNITED STATES) |
| Trial ID | NIH-10842722 on ClinicalTrials.gov |
What this research studies
This research investigates the role of extrachromosomal DNAs (ecDNA) in both normal development and how they contribute to diseases like cancer. By examining how these DNA fragments are produced and regulated, the research aims to uncover their impact on drug resistance and cancer progression. Patients may benefit from insights gained about ecDNA, which could lead to new therapeutic targets and treatment strategies. The research employs a combination of laboratory experiments and analyses to understand the biological processes involved.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with cancer, particularly those experiencing drug resistance.
Not a fit: Patients with non-cancerous conditions or those not affected by drug resistance may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for cancer patients by targeting the mechanisms of drug resistance.
How similar studies have performed: While the role of ecDNA in cancer is an emerging field, preliminary studies suggest that understanding these mechanisms could lead to significant advancements in cancer treatment.
Where this research is happening
Aurora, UNITED STATES
- UNIVERSITY OF COLORADO DENVER — Aurora, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BLACK, JOSHUA CRANSTON — UNIVERSITY OF COLORADO DENVER
- Study coordinator: BLACK, JOSHUA CRANSTON
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Breast Cancer, Cancer Genes, Cancer-Promoting Gene, Cancers